Search results
Showing 46 to 60 of 74 results for cystic fibrosis
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Outside interests of the NICE board
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
This evidence summary has been updated and replaced by NICE guideline NG78.
Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)
This evidence summary has been updated and replaced by NICE guideline NG117.
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
This guidance has been updated and replaced by NICE technology appraisal guidance 988.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Discontinued Reference number: GID-TA10310
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
In development Reference number: GID-TA11372 Expected publication date: TBC